Table 3.
Pharmacodynamic Response to Atropine Sulfate Delivery
| DPIA (n=16) | AUTO (n=17) | ||||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | p value (n=16) | |
| Heart rate (bpm) | 18 | 12 | 23 | 13 | 0.07 |
| Systolic BP (mm Hg) | 9.3 | 7.8 | 10.5 | 12.4 | 0.92 |
| Diastolic BP (mm Hg) | 6.1 | 5.7 | 9.1 | 7.0 | 0.25 |
| Temperature (°C) | 1.0 | 0.5 | 0.7 | 0.5 | 0.11 |
| Pupil diameter R (mm) | 0.8 | 0.6 | 1.0 | 0.4 | 0.63 |
| Pupil diameter L (mm) | 0.8 | 0.7 | 0.8 | 0.4 | 0.99 |
| NPA (cm) | 5.9 | 5.7 | 8.9 | 8.4 | 0.18 |
| FEV1 (L) | 0.2 | 0.2 | 0.2 | 0.2 | 0.98 |
| FVC (L) | 0.1 | 0.1 | 0.1 | 0.2 | 0.83 |
MicroDose Therapeutx dry powder inhaler (DPIA): nominal dose 2 mg, output dose 1.95 mg; and AtroPen Auto-Injector (AUTO): 2 mg IM. Maximum increases from baseline are reported and compared. Comparisons were performed using the Wilcoxon signed rank test comparing differences between values (DPIA–AUTO). NPA, near point of accommodation.